HomeCompareCONXW vs ABBV

CONXW vs ABBV: Dividend Comparison 2026

CONXW yields 1063.26% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CONXW wins by $32234602.79M in total portfolio value
10 years
CONXW
CONXW
● Live price
1063.26%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32234602.89M
Annual income
$27,201,953,545,755.64
Full CONXW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CONXW vs ABBV

📍 CONXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCONXWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CONXW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CONXW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CONXW
Annual income on $10K today (after 15% tax)
$90,377.46/yr
After 10yr DRIP, annual income (after tax)
$23,121,660,513,892.29/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CONXW beats the other by $23,121,660,492,836.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CONXW + ABBV for your $10,000?

CONXW: 50%ABBV: 50%
100% ABBV50/50100% CONXW
Portfolio after 10yr
$16117301.50M
Annual income
$13,600,976,785,263.70/yr
Blended yield
84.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CONXW
No analyst data
Altman Z
9.9
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CONXW buys
0
ABBV buys
0
No recent congressional trades found for CONXW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCONXWABBV
Forward yield1063.26%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$32234602.89M$102.3K
Annual income after 10y$27,201,953,545,755.64$24,771.77
Total dividends collected$31853289.40M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CONXW vs ABBV ($10,000, DRIP)

YearCONXW PortfolioCONXW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$117,026$106,326.42$11,550$430.00+$105.5KCONXW
2$1,288,116$1,162,897.27$13,472$627.96+$1.27MCONXW
3$13,340,963$11,962,679.40$15,906$926.08+$13.33MCONXW
4$130,066,428$115,791,598.06$19,071$1,382.55+$130.05MCONXW
5$1,194,216,858$1,055,045,779.38$23,302$2,095.81+$1194.19MCONXW
6$10,331,082,798$9,053,270,759.89$29,150$3,237.93+$10331.05MCONXW
7$84,249,757,647$73,195,499,052.88$37,536$5,121.41+$84249.72MCONXW
8$648,004,920,939$557,857,680,257.50$50,079$8,338.38+$648004.87MCONXW
9$4,703,410,600,754$4,010,045,335,349.40$69,753$14,065.80+$4703410.53MCONXW
10$32,234,602,888,563$27,201,953,545,755.64$102,337$24,771.77+$32234602.79MCONXW

CONXW vs ABBV: Complete Analysis 2026

CONXWStock

CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. The company was incorporated in 2020 and is based in Littleton, Colorado.

Full CONXW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CONXW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CONXW vs SCHDCONXW vs JEPICONXW vs OCONXW vs KOCONXW vs MAINCONXW vs JNJCONXW vs MRKCONXW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.